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CarcinogenesisIn normal epithelial cells hemidesmosomes mediate stable adhesion to the underlying basement membrane.
In carcinoma cells a functional and spatial dissociation of the hemidesmosomal complex is observed
stimulating the hypothesis that the β4 integrin may trigger essential signalling cascades determining cell
fate. In the present study we dissected the signalling pathways giving rise to PKB/Akt and ERK1/2 activation
in response to β4 ligation by 3E1. It was found that the activation of PKB/Akt is sensitive towards alterations
of the keratin ﬁlament as demonstrated by using KEB-7 cells that carry a keratin mutation typical for
epidermolysis bullosa simplex. Similar results were achieved by chemically induced keratin aggregations. Of
note, the signalling to ERK1/2 was not affected. ERK1/2 activation utilizes an EGF-R transactivation
mechanism as shown by dominant-negative expression experiments and also by treatment with a speciﬁc
inhibitor (AG1478). Downstream from the EGF-R the activation of ERK1/2 takes the prototypical signalling
cascade via Shc, Ras and Raf-1 as demonstrated by dominant-negative expression experiments. Taken
together our data deﬁne a new model of β4-dependent PKB/Akt and ERK1/2 activation demonstrating the
keratin ﬁlament as a structure necessary in signal transmission.nd Venerologie, Klinikum der
rankfurt/Main, Germany. Tel.:
S. Kippenberger).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Epidermal keratinocytes form the borderline to the external
environment by building a stratiﬁed epithelium with differentially
keratinized cells protecting the organism against physical, chemical
and microbial challenges. The lifelong maintenance of epidermal
renewal is warranted by a pool of stem cells located within the basal
layer. The onset of the differentiation program is inversely correlated
to cell anchorage [1]. Particularly, extracellular matrix receptors of the
integrin family were identiﬁed as important regulators of cell
homeostasis [2]. The prevention of ligand binding starts a program
of cellular differentiation marked by the exit of cell cycle, progressive
keratinization and ultimately the formation of horny scales that leave
the organism [3,4].
Surface receptors of the integrin family form heterodimers
composed of α and β subunits, which convey substrate speciﬁc
recognition. An assembly of α6 and β4 subunits serves as receptor of
laminin-5 the major constituent of the basement membrane [5].
Intracellularly, α6β4 connects to elements of the cytoskeleton,
namely to the keratin ﬁlament via the plaque proteins plectin (HD1)and BPAG1a (BP230) [6,7]. Keratins belong to a superfamily of
intermediate ﬁlament proteins that can be divided into two
subgroups, type I and type II keratins, based on biochemical
properties such as molecular weight and isoelectric point. Hetero-
polymers of type I and type II keratins form the intermediate
ﬁlaments which are expressed in epithelial cells throughout the
body. Generally, it is assumed that keratin ﬁlaments give structural
reinforcement to cells providing mechanical resilience. This as-
sumption is backed by the observation that keratin missense
mutations cause cell fragility disorders such as epidermolysis
bullosa simplex.
Additionally, α6β4 can connect to the actin ﬁlament and the
microtubule network [7–9]. Dynamic changes in the preferential
binding to the different cytoskeletal proteins seem to correlate with
aspects of the α6β4 function [8]. Besides architectural properties,
the α6β4 integrin has also strong implications for the migratory and
invasive behaviour of carcinoma cells [8,10–12]. In contrast to the
common observation that adhesion molecules are mostly down-
regulated to enable an invasive phenotype, it was found that in
various carcinomas the α6β4 integrin is overexpressed and
correlates with tumour progression [13–15]. Vice versa a loss of
α6β4 was found to reduce tumourigenicity [16,17]. Furthermore, it
was observed that the α6β4 integrin disappears from the hemi-
desmosomes during carcinogenesis and accumulates preferentially
in the F-actin rich cell protrusions. This redistribution is functionally
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in response to chemotactic stimulation indicating a contribution to
cell migration in carcinoma cells [8].
Additionally, it is shown that the α6β4 activates the anti-
apoptotic kinase PKB/Akt in a PI3K dependent fashion [10,18,19].
Our group could demonstrate that activation of the β4 subunit
facilitates cell adhesion to non-modiﬁed plastic in a PKB/Akt
dependent manner [20]. A constitutive activation of PKB/Akt is
described in various human cancers corroborating its role in cellFig. 1. Ligation of β4 by 3E1 induces phosphorylation and translocation of PKB/Akt and ERK1/
antibody 3E1 in HaCaT cells (a, c) and HEK-293 cells (b, d). Overnight serum-starved cells w
(5 µg/ml) for control. (e, f) HEK-293 cells were transiently transfected with β4Δcyt, a β4 that
cells were stimulated with 3E1 (5 µg/ml) for 5, 10 and 30 min. Proteins were obtained as de
speciﬁc antibodies directed against PKB/Akt (threonine-308, serine-473), and ERK1/2 (
antibodies directed against total PKB/Akt. The blot shows representative results. (n=3). (g)
control. After 30 min cells were ﬁxed, stained with phospho-speciﬁc antibodies against
Representative photographs are shown.survival [21–24]. Moreover, α6β4 also activates members of the
mitogen-activated protein kinase family [25,26]. Particularly, the
phosphorylation of JNK/SAPK and ERK1/2 was observed upon
plating onto laminin-5 [26]. Particularly, ERK1/2 which is a
modulator of proliferation, survival, differentiation and motility is
a promising target molecule in cancer therapy in this context [27].
Driven by the aforementioned observations we investigated
signaling cascades involved in the activation of PKB/Akt and ERK1/
2. Importantly, we provide evidence for a dissection of both2. Time course of PKB/Akt and ERK1/2 phosphorylation after treatment with β4-speciﬁc
ere incubated with 3E1 (5 µg/ml) for the indicated time intervals or with mouse IgG
lacks the cytoplasmic domain, and pcDNA3 for control. After serum-starvation for 16 h
scribed in Materials and methods, and Western blotting was performed with phospho-
threonine-202/ tyrosine-204), respectively. Equal loading was monitored by using
HaCaT cells were serum-starved for 16 h and then stimulated with 3E1 or mouse IgG for
PKB/Akt and ERK1/2, respectively. The nuclei in blue are stained by bisbenzimide.
942 S. Kippenberger et al. / Biochimica et Biophysica Acta 1803 (2010) 940–950pathways and a contribution of keratin ﬁlaments in PKB/Akt
activation.2. Materials and methods
2.1. Antibodies and reagents
The β4 integrin activating antibody (clone 3E1) was purchased
from Chemicon (Hofheim, Germany) and given to the cultures at a
ﬁnal concentration of 5 µg/ml. As control served mouse IgG
(Chemicon). For Western blotting the phosphorylation of ERK1/2
was detected using a phospho-speciﬁc antibody (Thr202/Tyr204;
Cell Signaling Technology, Frankfurt, Germany). An antibody
against total ERK1/2 (Cell Signaling Technology) served as loading
control. Phosphorylation of PKB/Akt (Ser473, Thr308) was
detected by phospho-speciﬁc antibodies (Cell Signaling Technolo-
gies). An antibody against total PKB/Akt (Cell Signaling Technol-
ogies) served as loading control. Antibodies raised against the
activated form of the epidermal growth factor receptor (EGFR) and
total EGFR were purchased from Transduction Laboratories (Hei-
delberg, Germany) and Santa Cruz (Heidelberg, Germany). For
monitoring transfections with dominant-negative expression vec-
tors the following antibodies against Rac-1 (Cell Signaling), RhoA
(Sigma-Aldrich, Munich, Germany), Ras (Cell Signaling), Cdc42
(Cell Signaling), shc (Cell Signaling), and EGFR (Transduction
Laboratories) were used. The PI3K inhibitors wortmannin and LY-
294002 and the speciﬁc inhibitor of the EGF receptor tyrosine
kinase AG1478 was purchased from Calbiochem-Novabiochem
(Darmstadt, Germany). Inhibitors were applied to the cells 1 h
before treatment with the antibodies. Acrylamide (Sigma-Aldrich)
induces reversible de-phosphorylation of keratins together with
reversible ﬁlament aggregation [28]. The effect of acrylamide forFig. 2. Inhibition of PI3K abrogates PKB/Akt activation in response to 3E1. HaCaT cells wer
wortmannin (25, 50, 100 nM) for 1 h. Then cells were stimulated with 3E1 (5 µg/ml). Aft
(threonine-308, serine-473), and ERK1/2 (threonine-202/tyrosine-204). Equal loading w
representative results. (n=3).3 h on keratins was documented by immunocytochemistry using
(see below). Antibodies used of immunocytochemistry are: Pan-
keratin antibody (Clone C-11, Sigma-Aldrich), phospho-Akt anti-
body (Ser473, clone D9E, Cell Signaling), and phospo-ERK1/2
antibody (Thr202/Tyr204, clone D13.14.4E, Cell Signaling).
2.2. Cell culture
The spontaneously immortalized human keratinocyte cell line
(HaCaT) (a generous gift from Norbert Fusenig, German Cancer
Research Institute, Heidelberg, Germany) was cultured in carbonate-
buffered Hank's medium with 5% fetal calf serum and 1% penicillin-
streptomycin (Biochrom KG, Berlin, Germany) at 37 °C in a 5% CO2
atmosphere. The human epithelial kidney line HEK-293was cultured in
Dulbecco'smodiﬁed Eagle'smedium (DMEM) containing 10% FCS. KEB-
7 cells expressing the severe Dowling–Meara type epidermolysis
bullosa simplex mutation (R125P) in the keratin 14 1A domain
were a kind gift from Birgitte Lane (Cancer Research UK Cell
Structure Research Group, University of Dundee, UK) [29]. KEB-7
cells were cultured in a supplemented DMEM/Ham's F12 medium
as described [30]. All experiments were done in agreement with
the local ethics commission.
2.3. Immunocytochemistry
For displaying alterations of the keratin ﬁlament HaCaT cells and
KEB-7 cells were seeded on plastic slides (LabTek, Nunc, Wiesbaden,
Germany) at a density of 4×105 cells per 1.78 cm2 and cultured
overnight under regular conditions. Consecutively, one part of the
HaCaT culture was treated with 100 mM acrylamide for 3 h. Then cells
were ﬁxed with acetone/methanol (50:50) for 5 min at room
temperature. Pan-keratin antibody was diluted 1:100 in phosphatee incubated with increasing concentrations of (a,b) LY294002 (5, 10, 20 µM) and (c,d)
er 10 and 30 min cells were lysed and protein extracts were probed against PKB/Akt
as monitored by using antibodies directed against total PKB/Akt. The blot shows
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the cells for 60 min at 37 °C. After three washes with PBS, cells were
incubated with alexa 546-coupled anti-mouse (MoBiTec, Göttingen,
Germany, 1:100 in PBS) for 30 min at 37 °C. In order to display cellular
location of phospho-PKB/Akt and phospho-ERK1/2 HaCaT cells were
serum-starved for 16 h cells and consecutively treated with 3E1
antibodies. After 30 min cells were ﬁxed with acetone/methanol and
consecutively stained with antibodies against phospho-PKB/Akt and
phospho-ERK1/2, respectively, diluted in PBS as aforementioned. TheFig. 3. Aggregation of keratin ﬁlaments abrogates PKB/Akt activation in response to 3E1. KEB
was induced by acrylamide were stimulated with either 3E1 or mouse IgG for control. (a
(100 mM) for 3 h and KEB-7 cells. The nuclei in blue are stained by bisbenzimide. (b) After 3
for 5, 10, and 30 min. Then protein extracts were analyzed using phospho-speciﬁc antibodies
tyrosine-204), respectively. Equal loading was monitored by using antibodies directed agai
incubated with increasing amounts of acrylamide (10, 25, 50, 100 mM) for 3 h before stim
aforementioned. (e) HaCaT cells or KEB-7 cells were stimulated with either 3E1 or mouse I
serine-473) or (f) ERK1/2 (threonine-202/tyrosine-204), respectively. Equal loading was m
results. (n=3).nuclei were stained by incubation with bisbenzimide (2 µg per mL,
20 min, RT). Finally, cells were rinsed three times with PBS and
examined by indirect immunoﬂuorescence.
2.4. Plasmids and transfection
HEK-293 cells were transiently transfected using Lipofectamine
2000 reagent (Invitrogen, Karlsruhe, Germany) according to the
manufacturer's instructions. The kinase-defective mutant of EGF-R-7 cells deﬁcient for a functional keratin 14 or HaCaT cells in which keratin aggregation
) Keratin ﬁlament staining of control cells (HaCaT), after treatment with acrylamide
h with 100 mM acrylamide cells were stimulated with 3E1 or mouse IgG (both 5 µg/ml)
directed against PKB/Akt (threonine-308, serine-473), and (c) ERK1/2 (threonine-202/
nst total PKB/Akt. The blot shows representative results. (n=3). (d) HaCaT cells were
ulation with 3E1 (5 µg/ml). After 30 min cell lysates were probed against PKB/Akt as
gG for control. After 30 min cell lysates were probed against PKB/Akt (threonine-308,
onitored by using antibodies directed against total PKB/Akt. Blots show representative
Fig. 4. Inhibition of the EGF-R tyrosine kinase by AG1478 abrogates ERK1/2 activation
in response to 3E1. HaCaT cells were pretreated with AG1478 for 1 h and then
stimulated with either 3E1 or mouse IgG for control. (a) After preincubation with
200 nM AG1478 cells were stimulated with 3E1 or mouse IgG (both 5 µg/ml) for 5, 10,
and 30 min. Then protein extracts were analyzed using phospho-speciﬁc antibodies
directed against PKB/Akt (threonine-308, serine-473), and (b) ERK1/2 (threonine-
202/tyrosine-204), respectively. Equal loading was monitored by using antibodies
directed against total PKB/Akt. The blot shows representative results. (n=3). (c)
HaCaT cells were incubated with increasing amounts of AG1478 (10, 50, 100, 500 mM)
for 1 h before stimulation with 3E1 (5 µg/ml). After 30 min cell lysates were probed
against phospho-ERK1/2 as aforementioned. Total ERK1/2 served loading control. The
blot shows representative results. (n=3).
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Science, Rehovot, Israel [31]. Because of a point mutation at position
721, lysine is replaced by alanine, the cytoplasmic kinase activity is
inhibited. Ras-N17 (serine to asparagine mutation at position 17) and
Ras-WT (wildtype) were from Clontech (Heidelberg, Germany). Raf-1
S621A (serine to alanine mutation at position 621) and Raf-1-WT
were from Clonetech. Cdc42-N17 and Rac-N17 (both, threonine to
asparagine at position 17) were kind gifts from Jonathan Chernoff, Fox
Chase Cancer Center, Philadelphia, USA [32]. ShcY239F/Y317F and
RhoA-N19 (threonine to asparagines at position 19) were kind gifts
from Filippo G. Giancotti, Memorial Sloan-Kettering Cancer Center,
New York, USA [33]. Expression plasmid of a mutated β4 lacking the
entire cytoplasmic domain with the exception of four amino acids
distal to the transmembrane sequence (β4Δcyt) was a kind gift from
Arthur M. Mercurio (Beth Israel Deaconess Medical Center-Dana,
Boston, USA) [34]. Cells were allowed to synthesize proteins under
regular conditions for 16 h. Before 3E1 antibody treatment cells were
serum-deprived for another 16 h.
2.5. Immunoblotting
Cells were lysed in 100 µl SDS sample buffer (62.5 mM Tris-HCl
[pH 6.8], 2% SDS, 10% glycerol, 50 mM DTT, 0.1% bromphenol blue),
sonicated and boiled for 5 min, and separated on SDS-polyacrylamide
gels. Consecutively, proteins were immunoblotted to a PVDF
membrane. The membrane was blocked in blocking buffer (TBS [pH
7.6], 0.1% Tween-20, 5% nonfat dry milk) for at least 3 h at 4 °C
followed by incubation with the primary antibody in TBS (pH 7.6),
0.05% Tween-20, and 5% BSA. The bound primary antibodies were
detected using anti-mouse IgG-horseradish peroxidase conjugate and
visualized with the ECL detection system (Amersham).
3. Results
3.1. 3E1 induces phosphorylation of PKB/Akt and ERK1/2
In overnight serum-starved HaCaT and HEK-293 cells, the ligation
of β4 by the activating antibody 3E1 induced a time-dependent
phosphorylation of PKB/Akt at both phosphorylation sites (Fig. 1a, b).
Furthermore, a time-dependent activation of ERK1/2 was found in
response to 3E1 in both epithelial cell species (Fig. 1c, d). Controls
treated with mouse IgG showed neither PKB/Akt nor ERK1/2
activation. In order to corroborate the target-speciﬁc effect of 3E1
HEK-293 cells were transfected with expression plasmids coding for
β4 mutants lacking the cytoplasmic domain (Fig. 1e, f). The Western
blot data presented show that in the absence of the signal-transducing
cytoplasmic β4 domain activation of PKB/Akt and ERK1/2 was
signiﬁcantly reduced. This gives evidence for a β4-dependent
activation of both kinases by 3E1. Furthermore, utilizing ﬂuorescent
microscopy the phosphorylation of PKB/Akt and ERK1/2 in response
to 3E1 was observed (Fig. 1g). Serum-starved HaCaT cells were
treated with 3E1 for 30 min, ﬁxed and then stained against phospho-
PKB/Akt (Ser473) and phospho-ERK1/2 (Thr202/Tyr204), respec-
tively. A clear increase in phosphorylation of both kinases in response
to 3E1 is documented. Consecutively, putative upstream regulators of
PKB/Akt and ERK1/2 were investigated. Fig. 2 presents data using
LY294002 (a, b) and wortmannin (c, d), both well established PI3K
inhibitors. Cells were pre-incubated with different amounts of the
PI3K inhibitor LY294002 (5, 10, 20 µM) and wortmannin (25, 50,
100 nM) for 1 h, and then treated with 3E1 for 10 or 30 min. Western
blot analysis shows that both PI3K inhibitors led to concentration-
dependent inhibition of 3E1-induced activation of PKB/Akt. ERK1/2
activation was insensitive towards treatment with wortmannin and
only marginally inhibited by LY294002. These ﬁndings indicate that
PKB/Akt activation by 3E1 is mediated by PI3K.3.2. Keratin aggregation inhibits PKB/Akt in response to 3E1
Hemidesmosomes connect to the intermediate ﬁlament. There-
fore, it seems likely that keratins may aid to signal transduction to
downstream elements. In the present approach acrylamide a drug
known to modify keratin integrity and a keratinocyte cell line (KEB-7)
derived from a patient suffering from epidermolysis bullosa simplex
were tested. Both, acrylamide treatment (100 mM) in HaCaT cells and
KEB-7 show aggregated keratin ﬁlaments as demonstrated by indirect
immunoﬂuorescence (Fig. 3a). Fig. 3b–d shows the effects of
acrylamide on the activation of PKB/Akt and ERK1/2 in response to
3E1. A pre-treatment with 100 mM acrylamide completely abrogated
the PKB/Akt signal (Fig. 3b) whereas activation of ERK1/2 was not
modiﬁed (Fig. 3c). In order to substantiate the effect of acrylamide on
PKB/Akt different concentrations were tested. Fig. 3d shows that
already 10 mM acrylamide block signiﬁcantly PKB/Akt activation in
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both phosphorylation sites was achieved. No cytotoxic effects as
measured by LDH-release were found in response to acrylamide (data
not shown). In order to corroborate the impact of the keratin ﬁlament
in cell signalling KEB-7 cells were compared to HaCaT (Fig. 3e, f).
Similarly to a treatment with acrylamide, KEB-7 cells show no
activation of PKB/Akt in response to 3E1 stimulation (Fig. 3e); the
activation pattern for ERK1/2 was not affected (Fig. 3f).
3.3. Inhibition of the EGF-R, Shc, Raf-1 and Ras inhibit ERK1/2 activation
in response to 3E1
In order to characterize the pathway giving rise to ERK1/2
activation in response to 3E1 treatment the relevance of the EGF-R
was investigated. The EGF-R signalling is a proto-typical pathway
leading to activation of both PKB/Akt [35–37] and ERK1/2 [38,39].
HaCaT cells were treated with AG1478, a speciﬁc inhibitor of the EGF
receptor tyrosine kinase, and then stimulated with 3E1 (Fig. 4a–c).Fig. 5. Dominant-negative expression of EGF-R and Shc abrogates ERK1/2 activation in resp
with (a, b) kinase-deﬁcient mutants of EGF-R (K721A) and pcDNA3 for control. After serum-
protein extracts were analyzed using phospho-speciﬁc antibodies directed against PKB/Akt
Equal loading was monitored by using antibodies directed against total PKB/Akt. (c) Activa
phospho-speciﬁc EGF-R antibody. Equal loading wasmonitored by using an antibody against
aforementioned under (a, b). The blot shows representative results. (n=3).The controls treated with 3E1 in the absence of AG1478 showed
phosphorylation of PKB/Akt (Fig. 4a) and ERK1/2 (Fig. 4b, c). Cells
treated with 200 nM AG1478 showed an attenuated activation of
PKB/Akt after 3E1 (threonine was 38% and serine 55% after 30 min as
determined by densitometric analysis) whereas activation of ERK1/2
was completely abrogated (Fig. 4b). The latter was further conﬁrmed
by using different concentrations of AG1478 (10, 50, 100, 500 nM)
(Fig. 4c). It was found that the 3E1-induced activation of ERK1/2 was
suppressed by AG1478 in a concentration dependent manner. Already
at 10 nM AG1478, the phosphorylation of ERK1/2 was distinctly
inhibited. At higher concentrations, this effect was more pronounced.
Additionally, to pharmacological inhibition, ectopic expression of
kinase-deﬁcient EGF-R (K721A) was tested (Fig. 5a, b). It was found
that overexpression of K721A in HEK-293 cells had only marginal
effects on 3E1-induced activation of PKB/Akt. Densitometric analysis
gave almost similar results for threonine phosphorylation whereas
the activation pattern of the serine phosphorylation was reduced to
approximately 40%. In contrast ERK1/2 activation was signiﬁcantlyonse to 3E1—marginal effects on PKB/Akt. HEK-293 cells were transiently transfected
starvation for 16 h cells were stimulated with 3E1 (5 µg/ml) for 5, 10 and 30 min. Then
(threonine-308, serine-473), and ERK1/2 (threonine-202/tyrosine-204), respectively.
tion of EGF-R in response to 3E1 was demonstrated in serum-starved cells by using a
total EGF-R. (d, e) Cells transfected with Shc-DN and pcDNA3 for control were treated as
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R (Fig. 5b). Furthermore, addition of 3E1 induced a slight but distinct
activation of the EGF-R (Fig. 5c) corroborating the functional link
between β4 and EGF-R in the signal transmission to ERK1/2. The
prototypical activation of ERK1/2 by EGF-R utilizes the adaptor
protein Shc and consecutively the Ras/Raf-1/MEK pathway [40]. In
order to test whether these molecules have relevance in the signal
transmission dominant-negative constructs of Shc (ShcY239F/Y317F)
(Fig. 5d, e), Raf-1 (Raf-1 S621A) (Fig. 6a, b) and Ras (Ras-N17) (Fig. 6c,
d) were utilized. It was found that ectopic overexpression of Shc-DN
slightly attenuated the 3E1-induced activation of PKB/Akt (Fig. 5d). Of
note, ERK1/2 activation was clearly suppressed by Shc-DN (Fig. 5e).
Likewise the expression of Raf-1-DN had only a marginal effect on
PKB/Akt (Fig. 6a) but led to a complete suppression of ERK1/2Fig. 6. Dominant-negative expression of Raf-1 and Ras abrogate ERK1/2 activation in respons
(a, b) Raf-1-DN and Raf-1-WT or with (c, d) Ras-N17 and Ras-WT, respectively. After serum-
protein extracts were analyzed using phospho-speciﬁc antibodies directed against PKB/Akt
Equal loading was monitored by using antibodies directed against total PKB/Akt. The blot sh
antibodies against ectopically expressed proteins.activation in response to 3E1 (Fig. 6b). A similar pattern was detected
after transfection with Ras-DN, almost no effect on PKB/Akt (Fig. 6c)
but complete suppression of ERK1/2 activation (Fig. 6d). In order to
control the transfection efﬁcacy protein expression of ectopically
induced proteins was tested (Fig. 6e).
3.4. Dominant-negative expression of members of small GTPases of the
Rho-family abrogate PKB/Akt activation in response to 3E1
It is well documented that Rho GTPases play a pivotal role in the
organisation of the cytoskeleton and cell locomotion with implica-
tions to α6β4-induced tumour invasion [10,41]. Therefore, the
contribution of RhoA, Cdc42 and Rac in 3E1-induced activation of
PKB/Akt and ERK1/2 was tested (Fig. 7). Ectopic overexpression ofe to 3E1 –marginal effects on PKB/Akt. HEK-293 cells were transiently transfected with
starvation for 16 h cells were stimulated with 3E1 (5 µg/ml) for 5, 10 and 30 min. Then
(threonine-308, serine-473), and ERK1/2 (threonine-202/tyrosine-204), respectively.
ows representative results. (n=3). (e) Transfection of HEK-293 cells was controlled by
Fig. 7. Dominant negative expression of Rho and Cdc42 abrogate PKB/Akt activation in response to 3E1. HEK-293 cells were transiently transfected with (a, b) Rho-N17 and pcDNA3,
(c, d) Cdc42-N17 and pcDNA3 or with (e, f) Rac-N17 and pcDNA3, respectively. After serum-starvation for 16 h cells were stimulated with 3E1 (5 µg/ml) for 5, 10 and 30 min. Then
protein extracts were analyzed using phospho-speciﬁc antibodies directed against PKB/Akt (threonine-308, serine-473), and ERK1/2 (threonine-202/tyrosine-204), respectively.
Equal loading was monitored by using antibodies directed against total PKB/Akt. The blot shows representative results. (n=3).
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PKB/Akt (Fig. 7a) while ERK1/2 activation was not altered (Fig. 7b).
Overexpression of Cdc42-N17 diminished activation of PKB/Akt
particularly at the threonine residue while effects on phospho-serine
were only moderate (Fig. 7c). Moreover, Cdc42-N17 shows no effect
on ERK1/2 (Fig. 7d). Interestingly, overexpression of Rac-N17
inhibited both, PKB/Akt and ERK1/2 (Fig. 7e, f). Regarding PKB/Akt
the inhibitory effect was particularly prominent for the threonine
residue and only moderate for serine. As dual phosphorylation at both
residues was found to be necessary for functional kinase activation of
PKB/Akt [42] the strong inhibitory effect found at threonine suggests
a blocking of this signalling molecule in our experiments.4. Discussion
The present study dissects the signalling cascade downstream
from the β4 integrin with particular respect to pivotal kinases
involved in carcinogenesis. Of note, we demonstrate activation of
PKB/Akt and ERK1/2 by distinct pathways and cross talk between
both pathways at the level of Rac. Moreover, we show EGF-R
transactivation by β4 giving rise to ERK1/2 phosphorylation. Of
particular interest is our ﬁnding that the keratin ﬁlament which is
linked to the β4 integrin is necessary for signal transmission to PKB/
Akt. This is surprising as the keratin ﬁlament is mostly regarded just as
a structural component within cell architecture. Clinically, missense
Fig. 8. Schematic model for β4 signalling. Ligation of β4 by 3E1 triggers a signalling
cascade utilizing the keratin ﬁlament, RhoA, Cdc 42 and PI3K conveying signals to PKB/
Akt. Additionally, EGF-R transactivation leads to ERK1/2 activation via Shc, Ras and Raf-
1. Rac mediates crosstalk between both signalling cascades.
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lysis bullosa simplex, an inherited blistering disease [43]. Also in vitro
studies utilizing cells from these patients demonstrated an attenuated
absorption of mechanical stress [30]. Moreover, it is proposed that
keratins might affect cell proliferation and protein synthesis [44,45].
Interestingly, in a set of non-epithelial neoplasms including melano-
ma keratins which are regularly absent become newly expressed [46].
In cloning experiments it was demonstrated that cell motility and
invasiveness of melanoma cells was signiﬁcantly increased by ectopic
keratin expression [46]. These observations suit well to our data
derived fromKEB-7 cells. The functional loss of the K5/K14 ﬁlament in
these cells abrogated the stimulation of PKB/Akt which is known as a
key regulator in oncogenesis [47]. Conﬁrmatory, the depletion of
some keratins in a transgenic mice model makes these animals less
susceptible to tumour formation which is maybe due to decreased
PKB/Akt activation [48].
Besides PKB/Akt a treatment with 3E1 also stimulates ERK1/2.
Previous studies have shown that 3E1 induces phosphorylation of
the β4 cytoplasmic domain followed by recruitment of adaptor
protein Shc yielding in ERK1/2 activation [25]. The SH2/PTB domain
of Shc also couples to other surface receptors including receptor
tyrosine kinases (RTK) [49–51]. In contrast our data demonstrate a
Shc activation after treatment with 3E1 sensitive towards AG1478
(data not shown) indicating that Shc is distal from EGF-R. Here we
give evidence that the transactivation of the EGF-R by 3E1 is
necessary to activate ERK1/2. As the activation of EGFR by 3E1 is
only moderate a mechanism implying signal ampliﬁcation is
suggested by others [52–54]. It seems likely that the high basal
level of EGF-R activation due to the engagement of other signalling
events synergizes with the here tested β4 activation on the level of
ERK1/2. Moreover, our data show that this ERK1/2 activation is
suppressed by dominant-negative expression of Ras and Raf-1
conﬁrming the prototypical ERK1/2 signalling cascade [55]. Since
the fundamental ﬁndings from Moro et al. [56] who ﬁrst showed
transactivation of the EGF-R by integrins a huge body of experi-
mental data has conﬁrmed this concept [57,58]. However, RTKs also
have impact on integrin-mediated events such as cell adhesion, cell
spreading, and cell migration [59–61]. This corroborates the
intimate functional connection between both receptor species
which is also documented by their close spatial assembly [8].
Transactivation of EGF-R is considered to play a key role in the
pathophysiology of hyperproliferative diseases such as cancer [62].
It is likely that EGF-R-dependent activation of Ras and ERK1/2 may
trigger the conversion into a malignant phenotype.
Lipscomb et al. [17] have shown that carcinoma cells devoid of
α6β4 are less invasive and show a reduced expression of VEGF
suggesting that this integrin modulates the expression of growth
factors. Additionally, the authors demonstrated elevation of apoptosis
markers such as annexin V, PI-positive cells and the presence of
caspase-3 cleavage products in carcinoma cells indicating that α6β4
integrin is a negative regulator of apoptosis. The aforementioned
induction of PKB/Akt via β4 stimulation supports this idea.
Furthermore, we show that dominant-negative expression of
small Rho GTPases suppressed PKB/Akt activation in response to
3E1. Small Rho GTPases belong to the Ras superfamily of proteins
divided into four main subfamilies: Rho, Rac, Cdc42, and others
lacking GTPase activity [63]. Amongst their pleiotropic functions in
cell physiology they play an important role in malignant transfor-
mation [64]. Here we show that RhoA, Cdc42 and Rac convey the
signal to PKB/Akt in response to 3E1. Besides the anti-apoptotic
properties of PKB/Akt this kinase was recently demonstrated to
increase substrate avidity in transformed epithelial cells after
stimulation with 3E1 [20]. In addition we give evidence in our
experiments that Rac also suppresses the activity of ERK1/2 in our
model. The close functional relationship between Rac and ERK1/2 is
also found by others [65,66]. This indicates the relevance of smallGTPases and particularly of Rac in the modulation of essential
kinases involved in carcinoma conversion.
In conclusion, our results describe a mechanism for the activation
of pivotal kinases by the activation of the β4 integrin. An important
aspect of our ﬁndings is that the keratin ﬁlament conveys signals from
the β4 integrin to PKB/Akt. The data derived from our experiments are
summarized in Fig. 8. From this it could be speculated that a
pharmacological separation of β4 and EGF-R signalling pathway may
offer a therapeutic option in the treatment of carcinomas. Particularly,
drugs that interfere with the integrity of the keratin ﬁlament may
have the potential to block anti-apoptotic signalling—also in non-
carcinoma neoplasms such as melanoma.
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